Trials / Unknown
UnknownNCT03864978
Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test
Safety and Efficacy of Rifaximin Delayed Release 400 mg Tablets in Patients With Moderate-to-severe Papulopustular Rosacea and Positive Lactulose Breath Test. A Multicenter Double-blind, Placebo-controlled Randomized Clinical Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 236 (estimated)
- Sponsor
- Alfasigma S.p.A. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Preliminary evidence suggests that treatment with rifaximin may be beneficial in patients with papulopustular rosacea. The present clinical trial is aimed to investigate the safety and efficacy of oral rifaximin delayed release versus placebo in adults with moderate-to-severe papulopustular rosacea (a.k.a. subtype II) and positive lactulose H2/CH4 breath test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin delayed release 400 mg tablet | Rifaximin delayed release |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2018-06-22
- Primary completion
- 2020-04-01
- Completion
- 2020-10-01
- First posted
- 2019-03-06
- Last updated
- 2019-03-11
Locations
12 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT03864978. Inclusion in this directory is not an endorsement.